Rapidly dissolving repaglinide powders producers by the ultra-rapid freezing process

AAPS PharmSciTech

Volumn 8, Issue 3, 2007, Pages

  Purvis, Troy ^a   Mattucci, Michael E ^b   Crisp, M Todd ^b   Johnston, Keith P ^b   Williams III, Robert O ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b The University of Texas at Austin   (United States)

Author keywords

Alkalizing agents; Dissolution enhancement; Repaglinide; Stability enhancement; Ultra rapid freezing

Indexed keywords

DIETHANOLAMINE; DODECYL SULFATE SODIUM; EXCIPIENT; PEROXIDE; REPAGLINIDE; SURFACTANT; TROMETAMOL; CARBAMIC ACID DERIVATIVE; PIPERIDINE DERIVATIVE;

ALKALINITY; ARTICLE; CHEMICAL COMPOSITION; CONTROLLED STUDY; CRYSTALLIZATION; DRUG DEGRADATION; DRUG FORMULATION; DRUG POTENCY; DRUG SOLUBILITY; DRUG STABILITY; DRY POWDER; FREEZE DRYING; FREEZING; PH; PHYSICAL CHEMISTRY; TEMPERATURE STRESS; ULTRA RAPID FREEZING; CHEMISTRY; PHARMACEUTICS; POWDER; SOLUBILITY; X RAY DIFFRACTION;

CARBAMATES; CHEMISTRY, PHARMACEUTICAL; FREEZING; HYDROGEN-ION CONCENTRATION; PIPERIDINES; POWDERS; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL; X-RAY DIFFRACTION;

EID: 34547196307     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Amidon GL. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413-420.
2. Dressman JB, Reppas C. In vitro-in vivo correlations for lipophilic, poorly water soluble drugs. Eur J Pharm Sci. 2000;11:S73-S80.
3. Hu JH, Johnston KP, Williams RO. Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs. Drug Dev Ind Pharm. 2004;30:233-245.
4. Hu JH, Johnston KP, Williams RO. Spray-freezing into liquid (SFL) particle engineering technology to enhance dissolution of poorly water soluble drugs: organic solvent versus organic/aqueous co-solvent systems. Eur J Pharm Sci. 2003;20:295-303.
5. Hu JH, Johnston KP, Williams RO. Rapid dissolving high potency danazol powders produced by spray freezing into liquid process. Int J Pharm. 2004;271:145-154.
6. Yu ZS, Rogers TL, Hu JH, Johnston KP, Williams RO. Preparation and characterization of microparticles containing peptide produced by a novel process: spray-freezing into liquid. Eur J Pharm Biopharm. 2002;54:221-228.
7. Rogers TL, Nelson AC, Hu JH, et al. A novel particle engineering technology to enhance dissolution of poorly water soluble drugs: spray-freezing into liquid. Eur J Pharm Biopharm. 2002;54:271-280.
8. Rogers TL, Johnston KP, Williams RO. Solution-based particle formation of pharmaceutical powders by supercritical or compressed fluid carbon dioxide and cryogenic spray-freezing technologies. Drug Dev Ind Pharm. 2001;27:1003-1015.
9. Vaughn JM, Gao X, Yacaman JM, Johnston KP, Williams RO. Comparison of powder produced by evaporative precipitation into aqueous solution (EPAS) and spray freezing into liquid (SFL) technologies using Z-contrast STEM and complimentary techniques. Eur J Pharm Biopharm. 2005;60:81-89.
10. Etzler FM, Sanderson MS. Particle size analysis: a comparative study of various methods. Part Part Syst Charact. 1995;12:217-224.
11. Waltersson JO, Lundgren P. The effect of mechanical comminution on drug stability. Acta Pharm Suec. 1985;22:291-300.
12. Leuenberger H. Spray freeze drying: the process of choice for low water soluble drugs? J Nanoparticle Res. 2002;4:111-119.
13. Maa YF, Nguyen PA, Sweeney T, Shire SJ, Hsu CC. Protein inhalation powders: spray drying vs. spray freeze drying. Pharm Res. 1999;16:249-254.
14. Costantino HR, Firouzabadian L, Hogeland K, et al. Protein spray freeze drying. Effect of atomization conditions on particle size and stability. Pharm Res. 2000;17:1374-1383.
15. Evans JC, Scherzer BD, Tocco CD. Preparation of nanostructured particles of poorly water soluble drugs via a novel ultra-rapid freezing technology. In: Svenson S, ed. Polymeric Drug Delivery Volume II- Polymeric Matrices and Drug Particle Engineering. New York, NY: American Chemical Society; 2004:2048-2057.
16. Hall RS, Board SJ, Clare AJ, Duffey RB, Playle TS, Poole DH. Inverse Leidenfrost phenomenon. Nature. 1969;224:266-267.
17. Gottfried BS, Lee CJ, Bell KJ. The Leidenfrost phenomenon: film boiling of liquid droplets. Int J Heat Mass Transfer. 1966;9:1167-1187.
18. Culy C, Jarvis B. Repaglinide, a review of its therapeutic use in Type 2 diabetes mellitus. Drugs. 2001;61:1625-1660.
19. Malaisse W. Repaglinide, a new oral antidiabetic agent: a review of recent preclinical studies. Eur J Clin Invest. 1 999;29:21-29.
20. Landgraf R, Frank M, Bauer C, Dieken M. Prandial glucose regulation with repaglinide: its clinical and lifestyle impact in a large cohort of patients with Type II diabetes. Int J Obes. 2000;24:S38-S44.
21. Wang FEI. Focus on repaglinide: an oral hypoglycemic agent with a more rapid onset and shorter duration of action than the sulfonylureas. Formulary . 1998;33:article 5.
22. Higuchi T, Connors K. Phase solubility diagram. Adv Anal Chem Instrum. 1965;4:117-212.
23. Gandhimathi M, Ravi T, Renu S. Determination of repaglinide in pharmaceutical formulations by HPLC and UV detection. Anal Sci. 2003;19:1675-1677.
24. Krishna Reddy KVSR, Babu J, Mathad V, et al. Impurity profile study of repaglinide. J Pharm Biomed Anal. 2003;32:461-467.
25. US Food and Drug Administration. Stability Testing: Drug substance stress testing. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use; February 6, 2003; Rockville, MD. Rockville, MD: US Food and Drug Administration; 2003.
26. Yamashita K, Nakate T, Okimoto K, et al. Establishment of new preparation method for solid dispersion formulation of tacrolimus. Int J Pharm. 2003;267:79-91.
27. Grell W, Hurnaus R, Griss G, et al. Repaglinide and related hypoglycemic benzoic acid derivatives. J Med Chem. 1998;41: 5219-5246.
28. Nakagaki M, Yokoyama S. Acid catalyzed hydrolysis of sodium dodecyl sulfate. J Pharm Sci. 1985;74:1047-1052.
29. Patel KC, Banker GS, DeKay HG. Anionic and cationic wetting agents in a hydrophilic ointment-base, I: choice of wetting agents. J Pharm Sci. 1961;50:294-300.
30. Newton JM, Rowley G, Tornblom JFV. Effect of additives on the release of drug from hard gelatin capsules. J Pharm Pharmacol. 1971;23:452-453.
31. Newton JM, Razzo FN. Interaction of formulation factors and dissolution fluid and the in vitro release of drug from hard gelatin capsules. J Pharm Pharmacol. 1 975;27:78P.
32. Valsami G, Dokoumetzidis A, Macheras P. Modeling of supersaturated dissolution data. Int J Pharm. 1999;181:153-157.
33. Hancock BC, Parks M. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res. 2000;17:397-404.
34. Hancock BC, Zograffi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci. 1997;86:1-12.
35. Raghavan SL, Trividic A, Davis AF, Hadgraft J. Effect of cellulose polymers on supersaturation and in vitro membrane transport of hydrocortisone acetate. Int J Pharm. 2000;193:231-237.
36. Gilbert JC, Hadgraft J, Bye A, Brookes LG. Drug release from Pluronic F-127 gels. Int J Pharm. 1986;32:223-228.
37. Couarraze G, Leclerc B, Conrath G, Falson-Rieg F, Puisieux F. Diffusion of a dispersed solute in a polymeric matrix. Int J Pharm. 1989;56:197-206.